Insider filing · MBX

Ali Behbahani bought $8.0M of MBX Biosciences (MBX)

Executed Sep 16 2024, disclosed Sep 17 2024, 1 day later.

Over the 21 trading sessions from the disclosed entry session (Sep 17 2024), the stock returned +9.6% (delay-adjusted); from the execution session (Sep 16 2024), -1.9%. Derived: entry at the session's open, exit at the close 20 sessions later.

AB Ali Behbahani Director profile →

Ali Behbahani (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in ADAP. Across 1 priced purchase filing, the average 21-session return was +6.2% from execution and -5.7% from disclosure (delay-adjusted; derived). The largest single filing was $15.0M of SGP (937,500 sh × $16.00, as filed), executed Feb 9.

MBX MBX MBX · 8 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→